Ideas, Formulations But also Strategies Needed for DMXAA

Of note, the kinetics of the decline in HBV DNA throughout treatment were nearly identical for sustained responders and relapsers but were quite different when HBsAg was assessed, suggesting that measurement of HBsAg concentrations may be more reliable to identify patients who will achieve SVR. In a recent study (49) evaluating 102 HBeAg-negative patients treated with PEG-IFN, a solid stopping rule was established at week 12 of treatment with combined declines in serum HBV DNA and HBsAg levels from baseline. Combining HBsAg and HBV DNA declines was the best predictor of a sustained http://www.selleckchem.com/products/Aloxistatin.html response defined as HBV DNA http://en.wikipedia.org/wiki/Resveratrol (NUCs) might be useful for monitoring treatment responses to predict HBsAg loss http://www.selleckchem.com/products/DMXAA(ASA404).html in patients who achieve HBV DNA suppression (54). Before a specific HBsAg level or a magnitude of change in HBsAg levels can be recommended to predict treatment outcomes, the meaning of these parameters must be understood in the treatment-free setting. Interestingly, two recent studies (55, 56) evaluated the correlation between HBsAg serum levels and the clinical and virological features of chronic HBV carriers at different phases of infection. Overall, 434 chronic carriers were studied: 62 immune-tolerant carriers (IT), 103 HBeAg-positive patients in the immune-clearance phase (IC), 118 HBeAg-negative carriers in the non-/low replicative phase (LC) and 151 patients with HBeAg-negative hepatitis. Two major findings were common to both studies: (i) median HBsAg levels differ significantly during the four phases of HBV infection and decline progressively from IT (4.5�C4.96?log10?IU/ml in Asian and European carriers) to LC (2.86�C3.09?log10?IU/ml in Asian and European carriers); (ii) HBsAg/HBV DNA ratios are significantly higher in LC (1.05 Asian�C1.17 European) compared to other patients (ratio range 0.55�C0.64). This suggests that HBsAg secretion is highly dynamic and varies throughout chronic HBV infection both quantitatively and qualitatively.